Changes in Hong Kong stocks | Pharmaceutical stocks continue to strengthen, Zhongsheng Pharmaceutical received $7 billion, BD led the rise in the first three quarters, and BD went overseas close to the whole of last year

The Zhitong Finance App learned that pharmaceutical stocks continued to rise this morning, led by innovative drugs and CRO concepts. As of press release, China Biopharmaceuticals (01177) rose 8.64% to HK$5.595; Kangfang Biotech (09926) rose 5.76% to HK$87.25; BeiGene (06160) rose 5.61% to HK$244.6; Cinda Biotech (01801) rose 4.70% to HK$89.05; Columbotai Biotech (06990) rose 4.66% to HK$463.0; Pharmaceuticals Kangde (02359) rose 4.65% to HK$207.0.

According to the news, the innovative drug sector is highly favorable. China Biopharmaceuticals announced after the market on November 4 that it has reached a major external license with multinational pharmaceutical company Boehringer Ingelheim for next-generation oncology treatments, covering 6 innovative drug pre-clinical projects. The company can receive a down payment of US$358 million, with a potential total of up to US$7 billion, setting a new record for the company's BD transaction amount. It is worth mentioning that according to the latest data disclosed by the National Development and Reform Commission, the total amount of foreign technology licensing transactions for China's innovative drugs reached about 130 billion US dollars in the first three quarters of this year, approaching the historical high of 135.6 billion US dollars for the whole of 2025.

Orient Securities pointed out that in terms of pharmaceuticals as a whole, revenue for the first three quarters of 2026 increased 1.4% year on year, net profit to mother increased 11.6% year on year, and net profit after deducting non-return to mother increased 18.3% year on year. Compared with 2025, the revenue growth rate rebounded slightly. Net profit from decline to mother and net profit from deducted to mother both changed from decline to increase, and the profit side growth rate was significantly higher than that on the revenue side, and the industry's profit recovery was further verified. Currently, the pharmaceutical industry is characterized by moderate revenue growth and rapid profit recovery. The growth rate of net profit after deduction is higher than net profit due to mother, and profit from main business continues to improve.